About CSL

CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives.

With major facilities in Australia, Germany, Switzerland, United Kingdom and the U.S., CSL employs over 14,000 employees working in more than 30 countries.

Our Areas of Expertise

Plasma Products

Human plasma is used to produce a wide range of life-saving medicines.

Our various businesses support all aspects of the process from the collection and testing of donated plasma through to the production of a range of plasma-derived products.

The key businesses involved with plasma products include:
  • CSL Behring is a global provider of plasma-derived & recombinant products. We operate one of the world's largest plasma collection networks through CSL Plasma
  • CSL Behring (Australia) is the chosen national plasma fractionator of Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan. We also manufacture and market in vitro diagnostic products through Seqirus Immunohaematology

Vaccines & Pharmaceuticals

In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza vaccine company in the world.

With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.

In Australia and New Zealand, Seqirus also markets a comprehensive range of vaccines and antivenoms as well as a range of pharmaceutical products supplied by other manufacturers.

Research & Development

Our activities at CSL are focused on new product development, life-cycle management and safety of our extensive product portfolio. CSL invests in the development of protein-based medicines for treating serious human diseases. Medicines can be made from human plasma or using recombinant biotechnology. More information is available in the Research & Development section.

LinkedIn Twitter Facebook Google+